Cartesian Therapeutics (RNAC) Competitors $9.84 -0.21 (-2.09%) Closing price 04:00 PM EasternExtended Trading$10.04 +0.20 (+2.02%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAC vs. LENZ, ZYME, GPCR, NTLA, RCUS, SION, STOK, SYRE, PRAX, and CRMDShould you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include LENZ Therapeutics (LENZ), Zymeworks (ZYME), Structure Therapeutics (GPCR), Intellia Therapeutics (NTLA), Arcus Biosciences (RCUS), Sionna Therapeutics (SION), Stoke Therapeutics (STOK), Spyre Therapeutics (SYRE), Praxis Precision Medicines (PRAX), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry. Cartesian Therapeutics vs. Its Competitors LENZ Therapeutics Zymeworks Structure Therapeutics Intellia Therapeutics Arcus Biosciences Sionna Therapeutics Stoke Therapeutics Spyre Therapeutics Praxis Precision Medicines CorMedix Cartesian Therapeutics (NASDAQ:RNAC) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Does the media prefer RNAC or LENZ? In the previous week, LENZ Therapeutics had 5 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 6 mentions for LENZ Therapeutics and 1 mentions for Cartesian Therapeutics. LENZ Therapeutics' average media sentiment score of 1.27 beat Cartesian Therapeutics' score of 0.93 indicating that LENZ Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, RNAC or LENZ? LENZ Therapeutics has lower revenue, but higher earnings than Cartesian Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$38.91M6.58-$77.42M-$52.83-0.19LENZ Therapeutics$5M223.90-$49.77M-$1.90-20.66 Is RNAC or LENZ more profitable? Cartesian Therapeutics' return on equity of 0.00% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cartesian TherapeuticsN/A N/A -6.36% LENZ Therapeutics N/A -25.63%-24.43% Do institutionals & insiders hold more shares of RNAC or LENZ? 87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 60.3% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 6.9% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, RNAC or LENZ? Cartesian Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Do analysts recommend RNAC or LENZ? Cartesian Therapeutics presently has a consensus target price of $40.00, suggesting a potential upside of 306.50%. LENZ Therapeutics has a consensus target price of $49.60, suggesting a potential upside of 26.37%. Given Cartesian Therapeutics' higher possible upside, equities analysts plainly believe Cartesian Therapeutics is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryLENZ Therapeutics beats Cartesian Therapeutics on 8 of the 15 factors compared between the two stocks. Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAC vs. The Competition Export to ExcelMetricCartesian TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$255.84M$3.10B$5.69B$9.68BDividend YieldN/A2.28%6.66%4.54%P/E Ratio-0.1920.9982.6526.40Price / Sales6.58360.50498.44197.40Price / CashN/A43.5325.7028.92Price / Book-36.449.8811.246.06Net Income-$77.42M-$53.38M$3.28B$266.05M7 Day Performance-8.72%-0.14%0.15%-0.07%1 Month Performance-20.19%9.18%8.34%5.83%1 Year Performance-29.51%7.53%54.21%17.88% Cartesian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNACCartesian Therapeutics1.9228 of 5 stars$9.84-2.1%$40.00+306.5%-28.0%$255.84M$38.91M-0.1964News CoveragePositive NewsLENZLENZ Therapeutics1.6074 of 5 stars$39.68-0.8%$49.60+25.0%+65.2%$1.14BN/A-20.88110Positive NewsZYMEZymeworks0.0335 of 5 stars$14.57-3.5%N/AN/A$1.14B$76.30M-15.02460News CoverageGap DownGPCRStructure Therapeutics2.2608 of 5 stars$18.57-5.3%$75.71+307.7%-49.4%$1.13BN/A-17.69136News CoveragePositive NewsNTLAIntellia Therapeutics4.7223 of 5 stars$11.38+8.2%$29.05+155.3%-49.4%$1.13B$57.88M-2.43600News CoveragePositive NewsRCUSArcus Biosciences1.9826 of 5 stars$10.18-3.3%$21.14+107.7%-38.1%$1.12B$258M-3.21500News CoveragePositive NewsSIONSionna TherapeuticsN/A$24.06-1.4%$38.50+60.0%N/A$1.08BN/A0.0035News CoverageSTOKStoke Therapeutics4.6184 of 5 stars$18.87-3.5%$25.57+35.5%+35.8%$1.07B$36.56M22.20100News CoveragePositive NewsSYRESpyre Therapeutics2.1911 of 5 stars$16.58-4.6%$53.40+222.1%-42.6%$1.05BN/A-4.8873News CoveragePositive NewsAnalyst DowngradePRAXPraxis Precision Medicines1.7247 of 5 stars$46.94-3.8%$85.88+82.9%-14.3%$1.03B$7.77M-3.82110Positive NewsCRMDCorMedix2.7866 of 5 stars$13.73+0.3%$17.33+26.2%+137.7%$1.02B$43.47M18.3130News CoveragePositive NewsShort Interest ↑ Related Companies and Tools Related Companies LENZ Competitors ZYME Competitors GPCR Competitors NTLA Competitors RCUS Competitors SION Competitors STOK Competitors SYRE Competitors PRAX Competitors CRMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAC) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAC Stock Alerts